Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597169 | 0.89 | SLC6A3 (0.67) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL595935 | 0.86 | ALDH1A1 (0.72) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL597494 | 0.84 | SLC6A3 (0.83) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL596663 | 0.82 | SLC6A2 (0.72) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL596566 | 0.82 | SLC6A3 (0.84) | SLC6A3SLC6A2SLC6A4MAPTSIGMAR1 | |
| SCHEMBL597602 | 0.81 | SLC6A2 (0.85) | SLC6A3SLC6A2SLC6A4KCNH2SIGMAR1 | |
| SCHEMBL11979746 | 0.79 | LMNA (0.67) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL595744 | 0.79 | SLC6A2 (0.85) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL10552245 | 0.78 | SLC6A4 (0.78) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 | |
| SCHEMBL10550540 | 0.78 | SLC6A4 (0.78) | SLC6A3SLC6A2SLC6A4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772319-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120208847-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8114379-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
| US-7381822-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-20050222166-A1 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2004063150-A2 | DIAGNOSTIC AND THERAPEUTIC ALKYL PIPERIDINE/PIPERAZINE COMPOUNDS AND PROCESS | THE GENERAL HOSPITAL CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222166-A1 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | HCRTR1, NR2E3, CHRNA3 | SLC6A3 20/4885SLC6A2 135/4885SLC6A4 192/4885 |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | NR2E3, DRD2, HCRTR1 | SLC6A3 23/4885SLC6A2 198/4885SLC6A4 247/4885 |
| US-20120208847-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | SNCA, NLN, DRD2 | SLC6A3 16/4885SLC6A2 53/4885SLC6A4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.